The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms

The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of ovarian neoplasms specifically related to the management of peritoneal surface malignancy. These guidelines are developed with input from leading experts, including surgical oncologists, medical oncologists, gynecologic oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.

[1]  Chicago Consensus Working Group.  The Chicago Consensus on Peritoneal Surface Malignancies: Management of Neuroendocrine Tumors , 2020 .

[2]  Chicago Consensus Working Group,et al.  The Chicago Consensus on Peritoneal Surface Malignancies: Management of Peritoneal Mesothelioma , 2020 .

[3]  Chicago Consensus Working Group,et al.  The Chicago Consensus on Peritoneal Surface Malignancies: Management of Colorectal Metastases , 2020 .

[4]  Chicago Consensus Working Group,et al.  The Chicago Consensus on Peritoneal Surface Malignancies: Management of Appendiceal Neoplasms , 2020 .

[5]  R. Yantiss,et al.  The Chicago Consensus on Peritoneal Surface Malignancies: Standards , 2020, Annals of Surgical Oncology.

[6]  R. Yantiss,et al.  The Chicago Consensus on Peritoneal Surface Malignancies: Management of Gastric Metastases , 2020, Annals of Surgical Oncology.

[7]  R. Yantiss,et al.  The Chicago Consensus on Peritoneal Surface Malignancies: Management of Desmoplastic Small Round Cell Tumor, Breast, and Gastrointestinal Stromal Tumors , 2020, Annals of Surgical Oncology.

[8]  K. Turaga,et al.  The Chicago Consensus on peritoneal surface malignancies: Methodology , 2020, Cancer.

[9]  N. Ahuja,et al.  The Chicago Consensus Guidelines for peritoneal surface malignancies: Introduction , 2020, Cancer.

[10]  R. Yantiss,et al.  The Chicago Consensus on peritoneal surface malignancies: Palliative care considerations , 2020, Cancer.

[11]  M. Parmar,et al.  Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. , 2018, The Lancet. Oncology.

[12]  A. Sood,et al.  Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer. , 2018, Gynecologic oncology.

[13]  Gabe S. Sonke,et al.  Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer , 2018, The New England journal of medicine.

[14]  A. Skardal,et al.  Peritoneal Metastases from Appendiceal Cancer. , 2018, Surgical oncology clinics of North America.

[15]  Danielle M. Enserro,et al.  A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study. , 2018 .

[16]  S. Msika,et al.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra‐appendicular origin , 2018, The British journal of surgery.

[17]  D. Bartlett,et al.  Peritoneal Carcinomatosis of Rare Ovarian Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Multi-Institutional Cohort from PSOGI and BIG-RENAPE , 2018, Annals of Surgical Oncology.

[18]  A. El-Agwany.  Laparoscopy and Computed Tomography Imaging in Advanced Ovarian Tumors: A Roadmap for Prediction of Optimal Cytoreductive Surgery , 2018, Gynecology and minimally invasive therapy.

[19]  D. Bartlett,et al.  A Multicenter Randomized Trial to Evaluate Hematologic Toxicities after Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin or Mitomycin in Patients with Appendiceal Tumors. , 2018, Journal of the American College of Surgeons.

[20]  H. Mackay,et al.  OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  N. Aaronson,et al.  Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer , 2018, The New England journal of medicine.

[22]  A. Reuss,et al.  Randomized controlled phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer – AGO DESKTOP III/ENGOT ov20 , 2017, Geburtshilfe und Frauenheilkunde.

[23]  R. Yantiss,et al.  The histopathological classification, diagnosis and differential diagnosis of mucinous appendiceal neoplasms, appendiceal adenocarcinomas and pseudomyxoma peritonei , 2017, Histopathology.

[24]  James X. Sun,et al.  Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[25]  Val Gebski,et al.  Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.

[26]  Anne Floquet,et al.  Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. , 2017, The Lancet. Oncology.

[27]  Ignace Vergote,et al.  Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. , 2016, The New England journal of medicine.

[28]  Joan L. Walker.  Intraperitoneal chemotherapy for ovarian cancer. , 2016, Gynecologic oncology.

[29]  Tom Walsh,et al.  Inherited Mutations in Women With Ovarian Carcinoma. , 2016, JAMA oncology.

[30]  G. Scambia,et al.  Cytoreductive Surgery Plus Platinum-Based Hyperthermic Intraperitoneal Chemotherapy in Epithelial Ovarian Cancer: A Promising Integrated Approach to Improve Locoregional Control , 2016, The oncologist.

[31]  W. Hohenberger,et al.  Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis , 2016, World Journal of Surgical Oncology.

[32]  B. Monk,et al.  Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. , 2016, The New England journal of medicine.

[33]  C. Compton,et al.  The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: Analysis of the National Cancer Data Base , 2016, Cancer.

[34]  L. Sobin,et al.  A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process , 2016, The American journal of surgical pathology.

[35]  D. Morris,et al.  Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-analysis. , 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[36]  D. Nonaka,et al.  Appendiceal Goblet Cell Carcinoids: Management Considerations from a Reference Peritoneal Tumour Service Centre and ENETS Centre of Excellence , 2015, Neuroendocrinology.

[37]  Jacobus Pfisterer,et al.  Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial , 2015, The Lancet. Oncology.

[38]  N. Aydin,et al.  Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA). , 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[39]  A. Kjær,et al.  Goblet Cell Carcinoids: Characteristics of a Danish Cohort of 83 Patients , 2014, PloS one.

[40]  J. Spiliotis,et al.  Cytoreductive Surgery and HIPEC in Recurrent Epithelial Ovarian Cancer: A Prospective Randomized Phase III Study , 2015, Annals of Surgical Oncology.

[41]  Jae-Weon Kim,et al.  Gynecologic Cancer InterGroup (GCIG) Consensus Review for Mucinous Ovarian Carcinoma , 2014, International Journal of Gynecologic Cancer.

[42]  K. Geisinger,et al.  Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy , 2014, Journal of surgical oncology.

[43]  D. Katsaros,et al.  Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[44]  A. Reuss,et al.  Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  R. Berri,et al.  Peritoneal Surface Disease Severity Score as a predictor of resectability in the treatment of peritoneal surface malignancies. , 2014, American journal of surgery.

[46]  Poonam K Sharma,et al.  Pseudomyxoma Peritonei: Inflammatory Responses in the Peritoneal Microenvironment , 2014, Annals of Surgical Oncology.

[47]  T. Jobo,et al.  Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. , 2013, The Lancet. Oncology.

[48]  T. Chua,et al.  Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastases , 2013, Journal of surgical oncology.

[49]  T. Chua,et al.  Carbohydrate antigen 19-9 (CA 19-9) is an independent prognostic indicator in pseudomyxoma peritonei post cytoreductive surgery and perioperative intraperitoneal chemotherapy. , 2013, Journal of gastrointestinal oncology.

[50]  Q. Huang,et al.  Clinical significance of ascites in epithelial ovarian cancer. , 2013, Neoplasma.

[51]  T. Gamblin,et al.  Right Hemicolectomy for Mucinous Adenocarcinoma of the Appendix: Just Right or Too Much? , 2013, Annals of Surgical Oncology.

[52]  S. Ahrendt,et al.  Significance of Serum Tumor Marker Levels in Peritoneal Carcinomatosis of Appendiceal Origin , 2013, Annals of Surgical Oncology.

[53]  T. Chua,et al.  Inflammatory Markers in Blood and Serum Tumor Markers Predict Survival in Patients With Epithelial Appendiceal Neoplasms Undergoing Surgical Cytoreduction and Intraperitoneal Chemotherapy , 2012, Annals of surgery.

[54]  V. Gebski,et al.  Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients , 2012, British Journal of Cancer.

[55]  D. Matei,et al.  Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. , 2012, The New England journal of medicine.

[56]  J. Esquivel,et al.  Laparoscopic Cytoreductive Surgery and HIPEC in Patients with Limited Pseudomyxoma Peritonei of Appendiceal Origin , 2012, Gastroenterology research and practice.

[57]  R. Wolff,et al.  Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  B. Weber,et al.  Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[59]  Gord Glendon,et al.  Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer , 2012 .

[60]  J. Yi,et al.  OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  Douglas F. Easton,et al.  Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. , 2012, JAMA.

[62]  J. Lee,et al.  Preoperative serum albumin is an independent prognostic predictor of survival in ovarian cancer , 2012, Medical Oncology.

[63]  B. Monk,et al.  Incorporation of bevacizumab in the primary treatment of ovarian cancer. , 2011, The New England journal of medicine.

[64]  Jacobus Pfisterer,et al.  A phase 3 trial of bevacizumab in ovarian cancer. , 2011, The New England journal of medicine.

[65]  Rochelle L. Garcia,et al.  Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing , 2011, Proceedings of the National Academy of Sciences.

[66]  P. Sugarbaker,et al.  Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin , 2010, Journal of surgical oncology.

[67]  R. Wolff,et al.  Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin , 2010, Cancer.

[68]  Jacobus Pfisterer,et al.  Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials , 2009, Cancer.

[69]  L. Sobin,et al.  Pathologic Classification and Clinical Behavior of the Spectrum of Goblet Cell Carcinoid Tumors of the Appendix , 2008, The American journal of surgical pathology.

[70]  B. Moran,et al.  Consensus statement on the loco‐regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei) , 2008, Journal of surgical oncology.

[71]  P. Sugarbaker,et al.  Treatment failure following complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from colorectal or appendiceal mucinous neoplasms , 2008, Journal of surgical oncology.

[72]  G. Witham,et al.  A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei , 2008, British Journal of Cancer.

[73]  M. Stauch,et al.  Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  R. Ozols,et al.  Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  D. Cella,et al.  Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  B. Karlan,et al.  Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  F. Zoetmulder,et al.  Survival Analysis of Pseudomyxoma Peritonei Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy , 2007, Annals of surgery.

[78]  G. Scambia,et al.  A Laparoscopy-Based Score To Predict Surgical Outcome in Patients With Advanced Ovarian Carcinoma: A Pilot Study , 2006, Annals of Surgical Oncology.

[79]  E. Venkatraman,et al.  Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum‐sensitive epithelial ovarian carcinoma , 2006, Cancer.

[80]  R. Ozols,et al.  Intraperitoneal chemotherapy for ovarian cancer. , 2006, The New England journal of medicine.

[81]  K. Geisinger,et al.  Appendiceal Neoplasms With Peritoneal Dissemination: Outcomes After Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy , 2006, Annals of Surgical Oncology.

[82]  R. Burger,et al.  Intraperitoneal cisplatin and paclitaxel in ovarian cancer. , 2006, The New England journal of medicine.

[83]  P. Sugarbaker,et al.  Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer , 2005, International seminars in surgical oncology : ISSO.

[84]  D. Chang,et al.  Utility of CEA and CA 19‐9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix , 2004, Journal of surgical oncology.

[85]  H. van Tinteren,et al.  Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  P. Sugarbaker,et al.  Results of Treatment of 385 Patients With Peritoneal Surface Spread of Appendiceal Malignancy , 1999, Annals of Surgical Oncology.

[87]  S. Orsulic,et al.  Ovarian Cancer , 1993, British Journal of Cancer.